These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16626169)

  • 1. Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis.
    Kepez A; Oto A; Dagdelen S
    BioDrugs; 2006; 20(2):121-35. PubMed ID: 16626169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New PPARγ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr(-/-) mice.
    Silva JC; César FA; de Oliveira EM; Turato WM; Tripodi GL; Castilho G; Machado-Lima A; de Las Heras B; Boscá L; Rabello MM; Hernandes MZ; Pitta MG; Pitta IR; Passarelli M; Rudnicki M; Abdalla DS
    Pharmacol Res; 2016 Feb; 104():49-60. PubMed ID: 26706782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
    Guo L; Tabrizchi R
    Pharmacol Ther; 2006 Jul; 111(1):145-73. PubMed ID: 16305809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin.
    Tsuchida A; Yamauchi T; Kadowaki T
    J Pharmacol Sci; 2005 Feb; 97(2):164-70. PubMed ID: 15725703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR ligands: potential therapies for metabolic syndrome.
    Akiyama TE; Meinke PT; Berger JP
    Curr Diab Rep; 2005 Feb; 5(1):45-52. PubMed ID: 15663917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
    Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
    Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
    Halabi CM; Sigmund CD
    Am J Cardiovasc Drugs; 2005; 5(6):389-98. PubMed ID: 16259527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of peroxisome proliferator-activated receptors γ (PPARγ) in obesity and insulin resistance].
    Chmielewska-Kassassir M; Woźniak LA; Ogrodniczek P; Wójcik M
    Postepy Hig Med Dosw (Online); 2013 Dec; 67():1283-99. PubMed ID: 24379269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
    Srivastava RA; Jahagirdar R; Azhar S; Sharma S; Bisgaier CL
    Mol Cell Biochem; 2006 Apr; 285(1-2):35-50. PubMed ID: 16477380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
    Zieleniak A; Wójcik M; Woźniak LA
    Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases].
    Scheen AJ; Paquot N
    Rev Med Liege; 2005 Feb; 60(2):89-95. PubMed ID: 15819371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G; Torres N; Tovar AR
    Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gluten-free diet reduces adiposity, inflammation and insulin resistance associated with the induction of PPAR-alpha and PPAR-gamma expression.
    Soares FL; de Oliveira Matoso R; Teixeira LG; Menezes Z; Pereira SS; Alves AC; Batista NV; de Faria AM; Cara DC; Ferreira AV; Alvarez-Leite JI
    J Nutr Biochem; 2013 Jun; 24(6):1105-11. PubMed ID: 23253599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update.
    Wang N; Yin R; Liu Y; Mao G; Xi F
    Circ J; 2011; 75(3):528-35. PubMed ID: 21325726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.